China: China's biopharma industry makes innovation-driven leap.

【Voice_over】 China's biopharmaceutical industry is now shifting from scale-driven growth to innovation-led development. Chimeric antigen receptor, or CAR, T-cell therapy, is among the most advanced cancer treatments in the world. In east China's Nanjing City, this CAR T-cell therapy manufacturing facility under IASO Bio is one of the largest of its kind in the country. Here, every production step is digitally tracked with online monitoring, video surveillance and electronic barcode tracing to ensure the products' safety and effectiveness. Elsewhere in Nanjing City, this pharmaceutical company is home to six 10,000-liter stainless-steel bioreactor lines, with a localization rate of over 90 percent. The facility is the country's first approved production line for biosimilars at the 10,000-litre scale. 【Sound_bite】 Lu Jiansheng, General Manager, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.: "For this white chromatography filler, we mainly relied on imports from large foreign companies. The original purchase price was roughly 15,000 to 22,000 U.S. dollars per litre. Now we have achieved independent development. We have been able to reduce the cost of this filler to around 1,500 to 3,000 U.S. dollars per litre, dramatically lowering our drug production costs." 【Voice_over】 According to company officials, their R&D investment has exceeded 2.6 billion U.S. dollars over the past five years, with more than 100 innovative drugs in clinical trials. [Restrictions: No access Chinese mainland]